Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Aeglea Bio Therapeutics stock in Canada
Own Aeglea Bio Therapeutics shares in just a few minutes.
Aeglea Bio Therapeutics is a biotechnology business based in the US. Aeglea Bio Therapeutics stocks (AGLE.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.13 – an increase of 19.27% over the previous week. Aeglea Bio Therapeutics employs 92 staff and has a trailing 12-month revenue of around $7 million.
How to buy stocks in Aeglea Bio Therapeutics
- Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – AGLE – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- Can I buy shares in Aeglea Bio Therapeutics?
- Has coronavirus impacted Aeglea Bio Therapeutics shares?
- Aeglea Bio Therapeutics shares summary
- Compare share dealing platforms
- Is Aeglea Bio Therapeutics stock a buy or sell?
- Aeglea Bio Therapeutics performance over time
- Aeglea Bio Therapeutics's financials
- How volatile are Aeglea Bio Therapeutics shares?
- Does Aeglea Bio Therapeutics pay a dividend?
- Other common questions
Aeglea Bio Therapeutics stock price (NASDAQ:AGLE)Use our graph to track the performance of AGLE stocks over time.
Aeglea Bio Therapeutics shares at a glance
|Latest market close||$0.53|
|52-week range||$0.37 - $8.50|
|50-day moving average||$0.49|
|200-day moving average||$1.97|
|Wall St. target price||$3.58|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-1.09|
Compare stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Aeglea Bio Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Aeglea Bio Therapeutics price performance over time
|1 week (2022-09-21)||N/A|
|1 month (2022-08-29)||N/A|
|3 months (2022-07-01)||3.12%|
|6 months (2022-03-29)||N/A|
|1 year (2021-09-28)||N/A|
|2 years (2020-10-02)||-92.51%|
|3 years (2019-10-02)||7.51|
|5 years (2017-10-02)||5.01|
Aeglea Bio Therapeutics financials
|Revenue TTM||$7 million|
|Gross profit TTM||$-38,330,000|
|Return on assets TTM||-43.16%|
|Return on equity TTM||-86.14%|
|Market capitalisation||$27 million|
TTM: trailing 12 months
Aeglea Bio Therapeutics share dividends
We're not expecting Aeglea Bio Therapeutics to pay a dividend over the next 12 months.
Aeglea Bio Therapeutics share price volatility
Over the last 12 months, Aeglea Bio Therapeutics's shares have ranged in value from as little as $0.372 up to $8.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aeglea Bio Therapeutics's is 1.6576. This would suggest that Aeglea Bio Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Aeglea Bio Therapeutics overview
Aeglea BioTherapeutics, Inc. , a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015.
Stocks similar to Aeglea Bio Therapeutics
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More on investing
A simple guide to buying stocks in your favourite European soccer team.Read more…
Rethink how you grow your money with these green investment strategies and key green stocks.Read more…
Using our proprietary algorithm, we searched the TSX, NYSE and Nasdaq to find the 10 best penny stocks to buy now.Read more…
More guides on Finder
How to buy NFI Group stock in Canada
Steps to owning and managing NFI stock, with 24-hour and historical pricing before you buy.
How to buy Laser Photonics Corp (LASE) stock in Canada when it goes public
Everything we know about the Laser Photonics Corp IPO plus information on how to buy in.
How to buy YanGuFang International Group (YGF) stock in Canada when it goes public
Everything we know about the YanGuFang International Group IPO plus information on how to buy in.
How to buy ParaZero Technologies (PRZO) stock in Canada when it goes public
Everything we know about the ParaZero Technologies IPO plus information on how to buy in.
How to buy Li Bang International Corporation (LBGJ) stock in Canada when it goes public
Everything we know about the Li Bang International Corporation IPO plus information on how to buy in.
How to buy Boustead Wavefront (BOUW) stock in Canada when it goes public
Everything we know about the Boustead Wavefront IPO plus information on how to buy in.
How to buy NYIAX (NYX) stock in Canada when it goes public
Everything we know about the NYIAX IPO plus information on how to buy in.
How to buy Adamas One Corp (JEWL) stock in Canada when it goes public
Everything we know about the Adamas One Corp IPO plus information on how to buy in.
How to buy BIOLIFE4D (SAVU) stock in Canada when it goes public
Everything we know about the BIOLIFE4D IPO plus information on how to buy in.